Pharma giant Glaxosmithkline plc (GSK) made "lemonade with lemons" using its pleuromutilin platform, Nabriva AG's chief medical officer (CMO), Elyse Seltzer, told BioWorld Today, but her company seems on the way to something sweeter with lefamulin, an antibiotic from the class due to report phase III LEAP1 data later this year in community-acquired bacterial pneumonia (CABP). Read More
DUBLIN – Shares in Xbiotech Inc. (NASDAQ:XBIT) fell by 41 percent Friday on news that its European application for its advanced colorectal cancer therapy Xilonix (MABp1), was likely to fail. Read More
Methods to manipulate gene expression in Bacteroides, the most common type of bacterium in the gut microbiome of Western populations, have been developed and reported by two separate research groups. Read More
AMSTERDAM – A combination of two Abbvie Inc. drugs, glecaprevir and pibrentasvir (G/P, previously ABT-493/ABT-530), helped 95 percent of noncirrhotic patients infected with the world's most common genotype of chronic hepatitis C virus (HCV) achieve undetectable levels of the virus in their blood at 12 weeks (SVR12), according to new data from the study, ENDURANCE-3, presented Saturday at the International Liver Congress. Read More
AMSTERDAM – The World Health Organization's (WHO) first global report on hepatitis estimates 325 million people worldwide are living with chronic hepatitis B or C virus (HBV or HCV) infections, with the vast majority lacking access to life-saving testing and treatment. The situation has left millions of people at risk of a slow progression to chronic liver disease, cancer and death, it said. Read More
HONG KONG – Having recently completed the acquisition of Belgium-based Ogeda SA, Astellas Pharma Inc. now has a potentially key drug candidate at its disposal as well as access to new programs to its drug development pipeline, all of which could provide boosts to its bottom line as it deals with an imminent patent cliff. (See BioWorld Today, April 4, 2017.) Read More
HONG KONG – Sanofi Pasteur Ltd.'s dengue vaccine has been granted a conditional registration for two years in Malaysia while phase IV studies are carried out. Read More
Apricus Biosciences Inc., of San Diego, priced an underwritten public offering of 5.03 million units, each consisting of one common share and one warrant to purchase 0.75 of a common share, at $1.40 per unit. Read More
Valeant Pharmaceuticals International Inc., of Laval, Quebec, said following the evaluation and approval of its patient access and pricing committee, the firm decided to list Siliq (brodalumab) injection at $3,500 per month. Read More
Aurinia Pharmaceuticals Inc., of Victoria, British Columbia, disclosed additional 48-week results from its global phase IIb AURA-LV (AURA) study in lupus nephritis during the National Kidney Foundation Spring Clinical Meetings in Orlando, Fla. Read More
